UBS raised the firm’s price target on Teva (TEVA) to $42 from $36 and keeps a Buy rating on the shares. Teva reported Q1 results that reinforce improving confidence in its outlook, supported by a broader pipeline expansion and the Emalex acquisition, the analyst tells investors in a research note. The stock is viewed as having re-rating potential given its relatively de-risked profile versus peers, attractive valuation, and reduced geopolitical concerns following confirmation of no material operational impact from its Israel headquarters, the firm says.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Teva Upgraded to $45 Price Target on Strong Execution, Emalex Acquisition, and Growing Neurology Pipeline Upside
- Teva price target raised to $45 from $42 at Truist
- Unusually active option classes on open April 29th
- Teva says making ‘great progress’ on Pivot to Growth strategy
- Teva says ‘on track’ to achieve 2027 financial targets